At a glance
- Originator Abbott Laboratories
- Class Antiasthmatics
- Mechanism of Action 5-lipoxygenase activating protein inhibitors; Leukotriene inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 30 Jan 2013 Discontinued - Preclinical for Asthma in USA (PO)
- 31 Aug 1998 No development reported - Preclinical for Asthma in USA (PO)
- 29 Aug 1996 Preclinical development for Asthma in USA (PO)